ChemicalBook > CAS DataBase List > Eltrombopag

Eltrombopag

Eltrombopag Structure
Eltrombopag
  • CAS No.496775-61-2
  • Chemical Name:Eltrombopag
  • CBNumber:CB71463423
  • Molecular Formula:C25H22N4O4
  • Formula Weight:442.47
  • MOL File:496775-61-2.mol
Eltrombopag Property
  • Melting point 242-244°C
  • Boiling point 656.8±65.0 °C(Predicted)
  • Density 1.33
  • storage temp. Keep in dark place,Inert atmosphere,Room temperature
  • solubility Soluble in DMSO (up to 55 mg/ml) or in ethanol (up to 14 mg/ml).
  • form solid
  • pka -1.26±0.40(Predicted)
  • color Orange
  • Stability Stable for 2 years from date of purchase as supplied. Solutions in DMSO or ethanol may be stored at -20° for up to 3 months.
  • InChI InChI=1S/C25H22N4O4/c1-14-10-11-19(12-15(14)2)29-24(31)22(16(3)28-29)27-26-21-9-5-8-20(23(21)30)17-6-4-7-18(13-17)25(32)33/h4-13,26,30H,1-3H3,(H,32,33)/b27-22-
  • InChIKey XDXWLKQMMKQXPV-QYQHSDTDSA-N
  • SMILES C1(C2=CC=CC(N/N=C3\C(=O)N(C4=CC=C(C)C(C)=C4)N=C\3C)=C2O)=CC=CC(C(O)=O)=C1
  • NCI Dictionary of Cancer Terms Promacta
  • FDA UNII S56D65XJ9G
  • NCI Drug Dictionary Promacta
  • ATC code B02BX05
  • UNSPSC Code 12352200
  • NACRES NA.77
Safety
Hazard and Precautionary Statements (GHS)
  • Symbol(GHS)
  • Signal wordDanger
  • Hazard statements H318-H373-H410-H302
  • Precautionary statements P273-P391-P501-P264-P270-P301+P312-P330-P501-P280-P305+P351+P338-P310-P260-P314-P501

Eltrombopag Chemical Properties,Usage,Production

  • Description ITP is an autoimmune disease in which antiplatelet antibodies accelerate the destruction of platelets. In addition, platelet production can be impaired because the antiplatelet antibodies can also damage megakaryocytes. Although the thrombocytopenia of ITP can be severe, signs of bleeding are usually only minor.
    Eltrombopag is an oral, small-molecule, nonpeptide TPO-receptor agonist. It initiates TPO-receptor signaling by interacting with the transmembrane domain of the receptor, thereby inducing proliferation and differentiation of cells in the megakaryocytic lineage. Eltrombopag is the second TPO-receptor agonist to reach the market behind romiplostim (Nplate), a recombinant fusion protein launched in 2008. Both drugs are specifically indicated for the treatment of thrombocytopenia in patients with chronic ITP who have had an insufficient response to corticosteroids, immunoglobulins, or splenectomy. Eltrombopag is supplied as the ethanolamine salt (also known as eltrombopag olamine).
    The most common adverse reactions associated with eltrombopag were nausea, vomiting, mennorrhagia, myalgia, paresthesia and cataracts. Eltrombopag is derived in five synthetic steps starting from 2-bromo-6-nitroanisole, via Suzuki coupling reaction with 3-carboxyphenylboronic acid to a biphenyl intermediate, followed by cleavage of the methyl ether moiety with hydrobromic acid, and reduction of the nitro group to an amino group under catalytic hydrogenation conditions. Subsequently, the amino group is diazotized with sodium nitrite and hydrochloric acid, and the diazonium intermediate is condensed with 1-(3,4-dimethylphenyl)-3-methyl-2,5-dihydro-1H-pyrazol-5-one to produce eltrombopag.
  • Chemical Properties Orange to Red Solid
  • Originator Ligand Pharmaceuticals (US)
  • Uses Eltrombopag (SB-497115-GR, Promacta, Revolade) is a small molecule agonist of the c-mpl (TpoR) receptor with an IC50 of 0.69 μM for the inhibition of hERG K+ channel tail current. In preclinical studies, the compound was shown to interact selectively with
  • Uses An agonist of the Thrombopoietin (Tpo) receptor, used as treatment for thrombocytopenia.
  • Definition ChEBI: A hydrazine in which each nitrogen atom is substituted, one by a 3'-carboxy-2-hydroxy[1,1'-biphenyl]-3-yl group and the other by a 1-(3,4-dimethylphenyl)-3-methyl-5-oxo-1,5-dihydro-4H-pyrazol-4-ylidene group. A small molecule agonist of the c-mpl (TpoR) receptor (the physiological target of the hormone thrombopoietin), it has been developed as a medication for conditions that lead to thrombocytopenia (abnormally low platelet counts).
  • brand name Promacta
  • Clinical Use Thrombopoetin receptor agonist:
    Treatment of chronic immune idiopathic thrombocytopenic purpura (ITP)
    Chronic hepatitis C associated thrombocytopenia (HCV)
    Severe aplastic anaemia
  • Synthesis The synthesis of Eltrombopag is as follows:
    At room temperature, add 8.02g (20.0mmol) compound of formula V, 3.98g (24.0mmol) 3-carboxyphenylboronic acid, 8.48g (80.0mmol) sodium carbonate, 1.46g (2.0mmol) PdCl2dppf into a 250mL three-necked flask, 80mL ethanol, 65mL water, nitrogen protection, heated to 80, reacted for 10h, cooled to room temperature, added 60mL water, filtered, the filtrate was adjusted to pH 1-2 with 2M hydrochloric acid, a red solid was precipitated, filtered, and the filter cake was ethanol/water ( v/v=1:1, 40mL) beating, filtering, and drying to obtain 7.58g, the yield is 85.8%, and the purity is 99.40%.
    synthesis of Eltrombopag.png
  • Drug interactions Potentially hazardous interactions with other drugs
    Ciclosporin: concentration of eltrombopag reduced.
    Statins: increased rosuvastatin concentration, may need to reduce rosuvastatin dose.
  • Metabolism Mainly hepatically metabolised through cleavage, oxidation by cytochrome P450 isoenzymes CYP1A2 and CYP 2C8 and conjugation with glucuronic acid, glutathione, or cysteine.
    Approximately 31% of a dose is eliminated in the urine as metabolites, and about 59% in the faeces (20% unchanged).
  • References 1) Xie?et al. (2018), Pharmacological characterization of eltrombopag, a novel orally active human thrombopoietin receptor agonist; J. Cell. Mol. Med.,?22?5367 2) Erickson-Miller?et al.?(2008),?Preclinical activity of eltrombopag (SB-497115), an oral, nonpeptide thrombopoietin receptor agonist; Stem Cells,?27?424 3) Alvarado?et al.?(2019),?Eltrombopag maintains human hematopoietic stem and progenitor cells under inflammatory conditions mediated by IFN-γ; Blood,?133?2043 4) Guenther?et al.?(2019),?Eltrombopag promotes DNA repair in human hematopoietic stem and progenitor cells; Exp. Hematol.?73?1 5) Vlachodimitropoulou?et al.?(2017),?Eltrombopag: a powerful chelator of cellular or extracellular iron (II) alone or combined with a second chelator; Blood,?130?1923 6) Kao?et al.?(2018),?Thrombopoietin receptor-independent stimulation of hematopoietic stem cells by eltrombopag; Science Transl. Med.,?10?eaas9563
Eltrombopag Preparation Products And Raw materials
Raw materials
Preparation Products
Eltrombopag Suppliers
Global(313)Suppliers
  • Supplier：
    AFINE CHEMICALS LIMITED
  • Tel：+86-0571-85134551
  • Email：sales@afinechem.com
  • Country：China
  • ProdList：15395
  • Advantage：58
  • Supplier：
    Capot Chemical Co.,Ltd.
  • Tel：+86-（0）57185586718<br/>+86-13336195806
  • Email：sales@capot.com
  • Country：China
  • ProdList：29730
  • Advantage：60
  • Supplier：
    Henan Tianfu Chemical Co.,Ltd.
  • Tel：+86-0371-55170693<br/>+86-19937530512
  • Email：info@tianfuchem.com
  • Country：China
  • ProdList：21628
  • Advantage：55

Related articles

Eltrombopag Spectrum
496775-61-2, EltrombopagRelated Search:
  • API
  • Inhibitors
  • Pharmaceuticals
  • Intermediates & Fine Chemicals
  • Heterocycles
  • Aromatics
  • Agonist
  • SB-497115-GR, Revolade, Promacta
  • 信号转导通路激酶抑制剂
  • 抑制剂
  • 化工试剂
  • 药靶配体
  • FDA批准的配体
  • 杂质对照品
  • 柏锦生物
  • 化学试剂
  • 化药杂质-艾曲波帕
  • 医用原料
  • 化工中间体
  • 医药原料
  • 血小板受体激动剂
  • 原料药
  • 小分子抑制剂
  • 医药原料药
  • 小分子抑制剂，天然产物
  • 496755-61-2
  • 艾曲波帕,10 MM DMSO 溶液
  • 伊屈泼帕(TPOR激动剂)
  • 艾曲波帕 (EQ-5)
  • 化合物IXAZOMIB
  • 艾曲波帕及中间体
  • 3'-[(2Z)-2-[1-(3,4-二甲基苯基)-1,5-二氢-3-甲基-5-氧代-4H-吡唑-4-亚苯基]肼基]-2'-羟基[1,1'-联苯]-3-羧酸
  • (Z)-3'-(2-(1-(3,4-二甲基苯基)-3-甲基-5-氧代-1H-吡唑-4(5H)-亚基)肼基)-2'-羟基-[1,1'-联苯基]-3-羧酸
  • 波帕
  • 艾曲波帕 ELTROMBOPAG OLAMINE
  • 埃尔托姆波帕杂质
  • 艾屈泼帕
  • 伊曲泼帕
  • 埃尔托姆波帕
  • 艾曲波帕
  • 伊屈泼帕
  • 3'-[2-[(2Z)-1-(3,4-二甲基苯基)-1,5-二氢-3-甲基-5-氧代-4H-吡唑-4-亚基]肼基]-2'-羟基-[1,1'-联苯]-3-羧酸
  • 伊曲波帕
  • 伊屈泼帕(艾曲波帕)
  • 伊屈泼帕杂质
  • 艾曲泼帕
  • 艾曲波帕游离碱
  • 496775-61-2
  • Eltrombopag - Bio-X ?
  • 3'-{(2Z)-2-[1-(3,4-dimethylphenyl)-3-methyl-5-oxo-1,5-dihydro-4H-pyrazol-4-ylidene] hydrazino}-2'-hydroxy-3-biphenylcarboxylic acid
  • (Z)-3'-(2-(1-(3,4-Dimethylphenyl)-3-methyl-5-oxo-1H-pyrazol-4(5H)-ylidene)hydrazinyl)-2'-hydroxy-[1,1'-biphenyl]-3-carboxylic acid
  • Ikuppa
  • Eltrombopa
  • Promacta
  • Eltrombopag [inn]
  • Eltrombopag free acid
  • Eltrombopag 13C4Q: What is Eltrombopag 13C4 Q: What is the CAS Number of Eltrombopag 13C4 Q: What is the storage condition of Eltrombopag 13C4 Q: What are the applications of Eltrombopag 13C4
  • Eltrombopag (SB-497115)

Home

My